GlassScriptPhysician profile
Reymond Meadaa
NPI 1669441283
$3,973.75
in general payments reported to CMS, 2019-2025
26 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,797 · 2020: $369 · 2021: $623 · 2022: $330 · 2023: $399 · 2024: $284 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $854.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,271.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $623.58 | 2020-2025 | Leqvio |
| Abiomed | $352.70 | 2021-2023 | Impella |
| Abbott Laboratories | $278.51 | 2019-2025 | Merlin@Home, Aveir, Jot Dx |
| Janssen Pharmaceuticals, INC | $233.58 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $229.17 | 2021-2025 | Verquvo |
| Amgen INC. | $217.52 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $171.85 | 2019-2024 | |
| Astellas Pharma US INC | $99.99 | 2019 | |
| Pfizer INC. | $79.32 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $73.27 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $46.58 | 2025 | Assure Wcd |
| Novo Nordisk INC | $39.07 | 2024 | Wegovy, Rybelsus, Ozempic |
| Irhythm Technologies, INC. | $35.84 | 2022-2023 | Zio Xt Patch |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.38 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $28.00 | 2021-2022 | |
| Atricure, INC. | $27.42 | 2024 | |
| Cardiovascular Systems INC. | $23.96 | 2021-2022 | |
| Bard Peripheral Vascular, INC. | $17.16 | 2021 | |
| Medtronic, INC. | $16.36 | 2023 | Venaseal |
| Ethicon US, LLC | $15.96 | 2025 | Stratafix |
| Lexicon Pharmaceuticals, INC. | $14.11 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $14.04 | 2019 | |
| Itamar Medical INC | $13.61 | 2023 | Watchpatone |
| Boston Scientific Corporation | $11.50 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reymond Meadaa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.